{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:00:10Z","timestamp":1792807210783,"version":"4.5.0"},"reference-count":24,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2024,12,23]]},"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1136\/ejhpharm-2024-004353","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:20:35Z","timestamp":1736428835000},"page":"183-186","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Drugs associated with tachyphylaxis: results from a retrospective pharmacovigilance study using disproportionality analysis"],"prefix":"10.1136","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3811-6503","authenticated-orcid":false,"given":"Kannan","family":"Sridharan","sequence":"first","affiliation":[{"name":"Pharmacology & Therapeutics, College of Medicine and Health Sciences, Arabian Gulf University, Manama, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"2026022302200623000_33.2.183.1","unstructured":"Stedman\u2019s medical dictionary. 28th edn. Philadelphia: Lippincott, Williams, and Wilkins, 2005."},{"key":"2026022302200623000_33.2.183.2","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jad.2018.10.357","article-title":"Tachyphylaxis in major depressive disorder: A review of the current state of research","volume":"245","author":"Kinrys","year":"2019","journal-title":"J Affect Disord"},{"key":"2026022302200623000_33.2.183.3","unstructured":"Biased \u03b2-agonists may provide better control of asthma and other obstructive lung diseases, drug discovery study shows. Available: https:\/\/hscweb3.hsc.usf.edu\/blog\/2021\/11\/22\/biased-%CE%B2-agonists-may-provide-better-control-of-asthma-and-other-obstructive-lung-diseases-drug-discovery-study-shows\/ [Accessed 18 Sep 2024]."},{"key":"2026022302200623000_33.2.183.4","first-page":"89","article-title":"Detecting Rare Adverse Events in Postmarketing Studies: Sample Size Considerations","volume":"40","author":"Wu","year":"2006","journal-title":"Ther Innov Regul Sci"},{"key":"2026022302200623000_33.2.183.5","doi-asserted-by":"crossref","unstructured":"Sridharan K , Sivaramakrishnan G . A pharmacovigilance study assessing risk of angioedema with angiotensin receptor blockers using the US FDA Adverse Event Reporting System. Expert Opin Drug Saf 2024;1\u20138. doi:10.1080\/14740338.2024.2393279","DOI":"10.1080\/14740338.2024.2393279"},{"key":"2026022302200623000_33.2.183.6","unstructured":"FDA adverse event reporting system (FAERS) public dashboard. Available: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis [Accessed 17 Sep 2024]."},{"key":"2026022302200623000_33.2.183.7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081990","article-title":"Navigating duplication in pharmacovigilance databases: a scoping review","volume":"14","author":"Kiguba","year":"2024","journal-title":"BMJ Open"},{"key":"2026022302200623000_33.2.183.8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.therap.2017.08.006","article-title":"Case-non case studies: Principles, methods, bias and interpretation","volume":"73","author":"Faillie","year":"2018","journal-title":"Therapie"},{"key":"2026022302200623000_33.2.183.9","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677"},{"key":"2026022302200623000_33.2.183.10","doi-asserted-by":"crossref","unstructured":"Poluzzi E , Raschi E , Piccinni C , et al . Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). In: Data mining applications in engineering and medicine. InTech, 2012. Available: http:\/\/dx.doi.org\/10.5772\/50095 [accessed 9 Dec 2024].","DOI":"10.5772\/50095"},{"key":"2026022302200623000_33.2.183.11","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0204-5"},{"key":"2026022302200623000_33.2.183.12","doi-asserted-by":"crossref","first-page":"18954","DOI":"10.5070\/D3197018954","article-title":"Tachyphylaxis to topical glucocorticoids; what is the evidence?","volume":"19","author":"Taheri","year":"2013","journal-title":"Dermatol Online J"},{"key":"2026022302200623000_33.2.183.13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4103\/0019-5049.147183","article-title":"An ultra-rapid development of tachyphylaxis to nitroglycerin","volume":"58","author":"Hegde","year":"2014","journal-title":"Indian J Anaesth"},{"key":"2026022302200623000_33.2.183.14","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2011.204685"},{"key":"2026022302200623000_33.2.183.15","unstructured":"Statler AK , Maani CV , Kohli A . Ephedrine. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2024. Available: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547661\/ [accessed 19 Sep 2024]."},{"key":"2026022302200623000_33.2.183.16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300263"},{"key":"2026022302200623000_33.2.183.17","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/00003246-199710000-00030","article-title":"Propofol and midazolam for sedation of the critically ill","volume":"25","author":"Swann","year":"1997","journal-title":"Crit Care Med"},{"key":"2026022302200623000_33.2.183.18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/JCP.0000000000001839","article-title":"A Case of Tachyphylaxis After Long-Term Intravenous Racemic Ketamine for Treatment-Resistant Depression","volume":"44","author":"Cavalcanti","year":"2024","journal-title":"J Clin Psychopharmacol"},{"key":"2026022302200623000_33.2.183.19","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/JPR.S114959","article-title":"Sedation with a remifentanil infusion to facilitate rapid awakening and tracheal extubation in an infant with a potentially compromised airway","volume":"9","author":"Naples","year":"2016","journal-title":"J Pain Res"},{"key":"2026022302200623000_33.2.183.20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/HYPERTENSIONAHA.121.17977","article-title":"Angiotensin II Type 1 Receptor Tachyphylaxis Is Defined by Agonist Residence Time","volume":"79","author":"Duarte","year":"2022","journal-title":"Hypertension"},{"key":"2026022302200623000_33.2.183.21","unstructured":"Cabergroline FDA package insert. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020664s011lbl.pdf [Accessed 9 Dec 2024]."},{"key":"2026022302200623000_33.2.183.22","unstructured":"Oxcarbazepine FDA package insert. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021014s036lbl.pdf [Accessed 9 Dec 2024]."},{"key":"2026022302200623000_33.2.183.23","unstructured":"Propofol FDA package insert. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019627s062lbl.pdf [Accessed 9 Dec 2024]."},{"key":"2026022302200623000_33.2.183.24","unstructured":"Cisatracurium FDA package insert. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020551s019lbl.pdf [Accessed 9 Dec 2024]."}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2024-004353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:20:18Z","timestamp":1771842018000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2024-004353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/ejhpharm-2024-004353"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2024-004353","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]}}}